Trial Profile
A Phase I Study Inhibiting Telomerase to Reverse Trastuzumab Resistance in HER2+ Breast Cancer.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Imetelstat (Primary) ; Trastuzumab
- Indications Advanced breast cancer
- Focus Adverse reactions
- 26 Oct 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 10 Oct 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 11 Oct 2011 Planned End Date changed from 1 Jan 2014 to 1 Aug 2013 as reported by ClinicalTrials.gov.